Guy Brannon, MD
Psychiatry · Shreveport, LANPI 1164481875
Payments from drug & device makers
Across 537 payments — averaging $2539.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$665K
- AbbVie$501K
- Sunovion Pharmaceuticals Inc.$119K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$33K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$18K
- Sumitomo Pharma America, Inc.$12K
- plus $14K from 20 others
What the payments were for
- Food & beverage$6,23797%
- Education$2063%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 121 | $665,355 |
| AbbVie(2 entities) | 121 | $501,451 |
| Sunovion Pharmaceuticals Inc. | 29 | $119,210 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 38 | $33,413 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $18,135 |
| Sumitomo Pharma America, Inc. | 5 | $11,896 |
| Hoffmann-la Roche Limited | 1 | $6,500 |
| GW Research Limited | 1 | $2,474 |
| Jazz Pharmaceuticals Inc. | 2 | $1,275 |
| Alkermes, Inc. | 41 | $823 |
| Neurocrine Biosciences, Inc. | 43 | $526 |
| Lundbeck LLC | 24 | $517 |
| Johnson & Johnson | 20 | $473 |
| Otsuka America Pharmaceutical, Inc. | 24 | $420 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $292 |
| Indivior Inc. | 8 | $191 |
| E.r. Squibb & Sons, L.L.C. | 11 | $174 |
| Braeburn Inc. | 7 | $149 |
| Livanova USA, Inc. | 3 | $118 |
| Axsome Therapeutics, Inc. | 5 | $106 |
| Vanda Pharmaceuticals Inc. | 4 | $103 |
| Ironshore Pharmaceuticals Inc. | 4 | $89 |
| Bioxcel Therapeutics, Inc. | 2 | $40 |
| Collegium Pharmaceutical, Inc. | 2 | $32 |
| Supernus Pharmaceuticals, Inc. | 1 | $24 |
| Almatica Pharma LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$480
- INVEGA SUSTENNA$125
How this compares
$1,363,799 in reported general payments places this provider in the 95th percentile of 474 psychiatry providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Paliperidone ErPaliperidone | 26 | $3,705 |
| Quetiapine Fumarate | 87 | $1,815 |
| Oxcarbazepine | 29 | $1,233 |
| Gabapentin | 61 | $792 |
| Divalproex Sodium | 35 | $722 |
| Ziprasidone Hcl | 16 | $584 |
| Trazodone Hcl | 46 | $552 |
| Aripiprazole | 18 | $516 |
| Olanzapine | 31 | $463 |
| Mirtazapine | 26 | $452 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $416 |
| Divalproex Sodium ErDivalproex Sodium | 16 | $381 |
| Methylphenidate Hcl | 12 | $376 |
| Prazosin Hcl | 21 | $311 |
| Risperidone | 27 | $304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Almatica Pharma LLCSertraline Hcl | $14 | $14731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 psychiatry providers in Louisiana.
Other psychiatry in Shreveport
- Gregory BrownShreveport$495K
- Jasjit SinghShreveport$420K
- James BookerShreveport$204K
- Shawn McNeilShreveport$105K
- Matthew MenardShreveport$101K
- Suresh SabbenahalliShreveport$10K
- Christopher BernadasShreveport$6K
- Daniel FeeneyShreveport$5K
- Kashinath YadalamLake Charles$3.8M
- Patrick HayesLake Charles$853K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.